Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Fish and Richardson
Farmers Insurance
Boehringer Ingelheim
Dow
Baxter
Harvard Business School
Fuji
Mallinckrodt

Generated: July 22, 2018

DrugPatentWatch Database Preview

Daiichi Company Profile

« Back to Dashboard

Summary for Daiichi

Drugs and US Patents for Daiichi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo AZOR amlodipine besylate; olmesartan medoxomil TABLET;ORAL 022100-004 Sep 26, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-003 Oct 2, 2015 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-004 Oct 2, 2015 RX Yes Yes 7,955,619 ➤ Try a Free Trial Y ➤ Try a Free Trial
Daiichi Sankyo Inc MORPHABOND ER morphine sulfate TABLET, EXTENDED RELEASE;ORAL 206544-003 Oct 2, 2015 RX Yes No 7,955,619 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Daiichi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo WELCHOL colesevelam hydrochloride TABLET;ORAL 021176-001 May 26, 2000 6,066,678*PED ➤ Try a Free Trial
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-001 Oct 2, 2009 5,693,675*PED ➤ Try a Free Trial
Daiichi Sankyo BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-003 Jun 5, 2003 5,616,599*PED ➤ Try a Free Trial
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-002 Oct 2, 2009 5,679,717*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DAIICHI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 5 mg/20 mg and 10 mg/40 mg ➤ Subscribe 2008-02-11
➤ Subscribe Capsules 30 mg ➤ Subscribe 2009-02-27
➤ Subscribe Tablets 20 mg/12.5 mg ➤ Subscribe 2007-05-11
➤ Subscribe Tablets 625 mg ➤ Subscribe 2009-07-01
➤ Subscribe Tablets 10 mg/20 mg and 5 mg/40 mg ➤ Subscribe 2008-03-31
➤ Subscribe Tablets 5 mg, 20 mg and 40 mg ➤ Subscribe 2006-04-25
➤ Subscribe Tablets 40 mg/12.5 mg and 40 mg/25 mL ➤ Subscribe 2007-02-15
➤ Subscribe Powder for Oral Suspension 1.875 g/Packet and 3.75 g/Packet ➤ Subscribe 2010-04-09

Non-Orange Book US Patents for Daiichi

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,707,296 Pharmaceutical composition ➤ Try a Free Trial
7,261,880 Methods of treating Syndrome X with aliphatic polyamines ➤ Try a Free Trial
8,377,428 Low salt forms of polyallylamine ➤ Try a Free Trial
7,342,014 Diamine derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Daiichi Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/037 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
2018005 Lithuania ➤ Try a Free Trial PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
0625 Netherlands ➤ Try a Free Trial PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
00499 Netherlands ➤ Try a Free Trial PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Accenture
Farmers Insurance
Argus Health
Fuji
McKinsey
Citi
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.